SB202190

别名: FHPI

目录号：S1077 Purity: 99.99%

SB202190是一种有效的p38 MAPK抑制剂，靶向作用于p38α/β，无细胞试验中IC50为50 nM/100 nM，有时用于代替SB 203580研究其在体内对SAPK2a/p38的潜在作用。SB202190 可通过诱导自噬和血红素氧化酶1来抑制内皮细胞的凋亡。SB202190可显著抑制Erastin依赖的铁死亡ferroptosis。

SB202190 Chemical Structure

CAS: 152121-30-7

规格	价格	库存
10mM (1mL in DMSO)	RMB 1091.41	现货
25mg	RMB 1189.49	现货
100mg	RMB 3017.14	现货
1g	RMB 13677.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

客户使用Selleck的SB202190发表文献177篇

产品质控

批次：纯度： 99.99%

99.99

SB202190相关产品

相关靶点	p38α p38β	点击展开
相关产品	Adezmapimod (SB203580) Doramapimod (BIRB 796) Ralimetinib (LY2228820) dimesylate PH-797804 VX-702 Losmapimod SB239063 Neflamapimod (VX-745) BMS-582949 Skepinone-L Asiatic Acid TAK-715 Pamapimod Pexmetinib SD 0006 R1487 p38 MAPK Rabbit Recombinant mAb PD 169316	点击展开
相关化合物库	激酶抑制剂库 MAPK抑制剂库细胞周期化合物库 TGF-beta/Smad信号通路库抗阿尔茨海默病化合物库	点击展开

p38 MAPK抑制剂选择性比较

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
MKN-45	Function Assay	10 µM	30 min	significantly decreases Il-1β-induced MMP2 and MMP9 mRNA expression	24479681
AGS	Function Assay	10 µM	30 min	significantly decreases Il-1β-induced MMP2 and MMP9 mRNA expression	24479681
MKN-45	Function Assay	10 µM	30 min	attenuates IL-1β-induced GA cell migration and invasion	24479681
AGS	Function Assay	10 µM	30 min	attenuates IL-1β-induced GA cell migration and invasion	24479681
MKN-45	Function Assay	10 µM	30 min	inhibits IL-1β-induced activation of p38	24479681
AGS	Function Assay	10 µM	30 min	inhibits IL-1β-induced activation of p38	24479681
HUVECs	Function Assay	10 µM	1 h	inhibits TNF-α-induced CXCL1 production	24487964
MC3T3-E1	Function Assay	30 μM	1 h	attenuates TNF-α-stimulated p38 MAPK phosphorylation	24502696
MC3T3-E1	Function Assay	0.3/3/30 μM	1 h	attenuates TNF-α-induced MMP-9 expression in a concentration-dependent manner	24502696
H1703	Function Assay	10 µM	6 h	significantly increases the levels of ubiquitin-conjugated MSH2 in pemetrexed-treated cell line	24530475
H520	Function Assay	10 µM	6 h	significantly increases the levels of ubiquitin-conjugated MSH2 in pemetrexed-treated cell line	24530475
H1703	Function Assay	10 µM	12 h	inhibits pemetrexed-elicited MSH2 protein stability	24530475
H520	Function Assay	10 µM	12 h	inhibits pemetrexed-elicited MSH2 protein stability	24530475
H1703	Function Assay	10 µM	1 h	decreases the pemetrexed-induced MSH2 mRNA and protein levels	24530475
H520	Function Assay	10 µM	1 h	decreases the pemetrexed-induced MSH2 mRNA and protein levels	24530475
AGS	Function Assay	5 μM	30 min	suppresses 1-induced caspase-8 and caspase-3 activation	24547878
PDL	Function Assay	20 μM	30 min	significantly inhibits the tensile force-mediated BMP-2 expression	24561081
macrophages	Function Assay	1 μM	4.5 h	completely inhibits MT-III-induced activation of NF-κB	24808633
MDDCs	Function Assay	10 μM	3.5 h	blocks EBOV GP, but not VSV G mediated entry into human MDDCs	24815087
MDDCs	Function Assay	0-15 μM	48 h	inhibits MIP-1a, MIP-1b and RANTES production	24815087
MDDCs	Function Assay	0-15 μM	48 h	suppresses IFN-α and IP-10 production	24815087
HSCs	Apoptosis Assay	25 μM	24 h	significantly attenuates TG-induced activated HSCs apoptosis	24961950
H9c2	Function Assay	50 μM	12 h	reduces LDH release and MMP loss	25245818
HaCaT	Function Assay	40 μM	3-24 h	reduces the accumulation of ZO-1	25435485
RAW 264.7	Function Assay	10 μM	30 min	attenuates the effects of OPG on osteoclast retraction	25461399
RAW 264.7	Function Assay	10 μM	30 min	induces characteristic vacuolation of OCs	25461399
WB	Function Assay	20 μM	30 min	decreases the LPS- or LTA-induced IL-6 and TNF-α production	25530682
THP-1	Function Assay	5 µM	2 h	significantly attenuates secretion of IL-1α induced by 27OHChol plus FSL-1	25598661
K562	Function Assay	0.25-1 μM	24 h	suppresses resveratrol-induced H2AX phosphorylation	25619392
BxPC-3	Function Assay	10 μM	1 h	enhances the autophagic effect	25632222
PANC-1	Function Assay	10 μM	1 h	enhances the autophagic effect	25632222
K562	Function Assay	10 μM	1 h	inhibits quinacrine-induced p38 MAPK phosphorylation	25684043
HPAEpiCs	Function Assay	1/3/10 μM	1 h	inhibits S1P time-dependently stimulated c-Jun phosphorylation	25734900
HPAEpiCs	Function Assay	1/3/10 μM	1 h	inhibits S1P-stimulated Akt phosphorylation	25734900
HPAEpiCs	Function Assay	1/3/10 μM	1 h	reduces S1P-induced ICAM-1 protein and mRNA expression and promoter activity	25734900
HaCaT	Function Assay	5 µM	24 h	inhibits IFN-α-induced CCL22 production levels	25834353
HaCaT	Function Assay	5 µM	24 h	inhibits IFN-γ-induced CCL22 production levels	25834353
SCC25	Function Assay	20 μM	24 h	increases autophagy level	25834400
MH7A	Apoptosis Assay	25 μM	24 h	reverses cell cycle arrest induced by XAN and caused apoptosis of cells via activation of JNK	25862966
SK-OV-3	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
OVCAR-3	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
HEY	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
AsPC-1	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
BxPC-3	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
MIA PaCa-2	Growth Inhibition Assay	20 μM	2 h	sensitizes cell lines to treatment with 2-DG and D-allose	25888489
MIA PaCa-2	Function Assay	20 μM	24 h	enhances cleavage of PARP when combined with glucose analogs	25888489
AsPC-1	Function Assay	20 μM	24 h	results in a modest inhibition of HIF-1α protein accumulation	25888489
BxPC-3	Function Assay	20 μM	24 h	results in a modest inhibition of HIF-1α protein accumulation	25888489
MIA PaCa-2	Function Assay	20 μM	24 h	results in a modest inhibition of HIF-1α protein accumulation	25888489
MIA PaCa-2	Function Assay	20 μM	24 h	reduced lactate accumulation in combination with both 2-DG and D-allose	25888489
HTSMCs	Function Assay	0.1/1/10 μM	1 h	inhibited CORM-2-induced HO-1 protein levels and mRNA expression	25921464
MG63	Apoptosis Assay	10/20/30 μM	24 h	significantly decreased the apoptosis rate of MG63 induced by CdCl2	25998312
MG63	Function Assay	10/20/30 μM	24 h	significantly decreases the level of phosphorylated p38 induced by CdCl2 in a concentration -dependent manner	25998312
rBMSCs	Function Assay	10 μM	2.5 h	depresses the phosphorylation of ERK and p38	26053266
MDA-MB-231	Function Assay	2 μM	24 h	lessenes CCL2 induction by TNFα	26100848
HCT-116	Function Assay	25 μM	30 min	attenuates the mRNA and protein expression of hBD-2 in responsive to DA	26223251
DCs	Function Assay	20 μM	1 h	decreases IL-12 production	24434636
HUVEC	Function Assay	20 μm	5 h	reduces cytokine expression levels in a concentration-dependent manner	24189062
A 549	Function Assay	50 μM	1 h	decreases the level of IL-8	24179688
H520	Function Assay	5/10 μM	1 h	decreases MSH2 protein as well as mRNA levels in gefitinib-exposed cell	24138903
H1703	Function Assay	5/10 μM	1 h	decreases MSH2 protein as well as mRNA levels in gefitinib-exposed cell	24138903
H520	Function Assay	10 µM	12 h	decreases MSH2 mRNA and protein stability in gefitinib-treated NSCLC cells	24138903
H1703	Function Assay	10 µM	12 h	decreases MSH2 mRNA and protein stability in gefitinib-treated NSCLC cells	24138903
MCF-7	Growth Inhibition Assay	10 μM	24 h	inhibits the CR108-induced cell death	24128853
HPAEpiCs	Function Assay	0.1/1/10 μM	1 h	inhibits TNF-α-induced cPLA2 protein and mRNA expression	24069158
podocytes	Function Assay	10 μM	1 h	inhibits TGFβ1-induced activation of p38MAPK and Erk1/2	24036212
MCF-7	Function Assay	10 μM	1 h	reduces the WA-induced phosphorylated p38 MAPK	24019090
MCF-7	Function Assay	10 μM	24 h	increases the WA-induced apoptosis	24019090
HAPI	Function Assay	10/20/40 μM	1 h	inhibits TCDD-induced p38/JNK MAPK phosphorylation	23969120
HAPI	Function Assay	20 μM	1 h	attenuates TCDD-induced activation of iNOS and production	23969120
HepG2	Function Assay	350 nM	24 h	inhibits the deguelin-induced activation of p38MAPK	23933198
AGS	Function Assay	10 μM	30 min	inhibits caspase-3 activation and inhibition of ERK	23850994
HepG2	Growth Inhibition Assay	0-50 μM	48 h	inhibits the proliferation in a dose dependent manner	23807508
BEL7404	Growth Inhibition Assay	0-50 μM	48 h	inhibits the proliferation in a dose dependent manner	23807508
HL7702	Growth Inhibition Assay	0-50 μM	48 h	inhibits the proliferation in a dose dependent manner	23807508
HepG2	Function Assay	0-50 μM	24 h	inhibits the phosphorylation of p38 downstream proteins MAPKAPK2, ATF2, MSK1 and HSP27 in a dose-dependent manner	23807508
BEAS-2B	Growth Inhibition Assay	10 μM	30 min	reverses the decrease of cell viability induced by HCI	23784034
BEAS-2B	Cytotoxity Assay	10 μM	30 min	inhibited the increase in LDH and IL-8 expression	23784034
BEAS-2B	Function Assay	10 μM	30 min	decreases the levels of caspase-3, Bad and fas	23784034
H9c2	Function Assay	0.01/0.1/1 μM	1 h	attenuates TNF-α-induced MMP-9 expression, mRNA levels, and promoter activity	23774252
H9c2	Function Assay	1 μM	1 h	reduces TNF-α directly stimulated p38 MAPK phosphorylation	23774252
U937	Function Assay	10 μM	1 h	abrogates the caffeine effect on MKP-1 and PP2Acα mRNA transcriptional levels	23707387
U937	Function Assay	10 μM	1 h	abrogates caffeine-induced MKP-1 down-regulation and PP2Acα up-regulation	23707387
U937	Function Assay	10 μM	1 h	suppresses c-Jun and CREB phosphorylation in caffeine-treated cells	23707387
A549	Function Assay	0.3/3/30 μM	1 h	significantly attenuates ATPγS-mediated COX-2 protein and mRNA expression and promoter activity	23680674
A549	Function Assay	10 μM	0-30 min	inhibits ATPγS induced p42/p44 MAPK and p38 MAPK phosphorylation	23680674
A549	Function Assay	10 μM	1 h	inhibits ATPγS induced NF-κB p65 subunit phosphorylation and NF-κB promoter activity	23680674
A549	Function Assay	10 μM	1 h	reduces ATPγS-stimulated cPLA2 phosphorylation	23680674
A549	Function Assay	10 μM	1 h	reduces ATPγS-enhanced enzymatic activity of cPLA2	23680674
PC12	Function Assay	10/20/40 μM	1 h	inhibits JNK and p38	23584357
HK-2	Apoptosis Assay	20 μM	24 h	inhibits ERK and p38MAPK	23543151
H9c2	Function Assay	1 μM	1 h	reduces TNF-α-induced MMP-9 mRNA levels and promoter activity	23353699
H9c2	Function Assay	1 μM	1 h	reduces TNF-α-enhanced AP-1 promoter activity	23353699
H1650	Function Assay	10 μM	1 h	decreases both protein and mRNA levels of ERCC1 in paclitaxel-exposed cells	23228696
H1703	Function Assay	10 μM	1 h	decreases both protein and mRNA levels of ERCC1 in paclitaxel-exposed cells	23228696
H1650	Growth Inhibition Assay	10 μM	1 h	enhances paclitaxel-induced cytotoxicity	23228696
H1703	Growth Inhibition Assay	10 μM	1 h	enhances paclitaxel-induced cytotoxicity	23228696
MDDCs	Growth Inhibition Assay		72 h	IC502.7μM	24815087
THP-1	Growth Inhibition Assay		72 h	IC50=4.7μM	24815087
MH7A	Growth Inhibition Assay		24 h	reinforces the inhibitory effects of XAN	25862966
RAW264.7	Antiinflammatory assay		10 mins	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method, IC50 = 16 μM.	22831798
BL21(DE3)	Function assay		60 mins	Inhibition of recombinant human N-terminal His6-tagged BRD4 expressed in Escherichia coli BL21(DE3) cells using biotinylated histone H4 peptide as substrate after 60 mins by AlphaScreen assay, IC50 = 3.4 μM.	28195723
medulloblastoma cells	Antiproliferative assay			Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 3.006 μM.	17417631
neural precursor cells	Antiproliferative assay			Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 8.063 μM.	17417631
RAW264.7	Function assay			Protection against Bacillus anthracis protective antigen and lethal toxin-diphtheria toxin chimeric protein mediated cytotoxicity in mouse RAW264.7 cells assessed as cell viability	17485504
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

特性

SB 202190 与SB 203580极为相似。

靶点

Ferroptosis ^[11]	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

体外研究(In Vitro)
体外研究活性	SB 202190显著抑制内源本底和和抗Fas抗体诱导的MAPKAPK 2活性，且抑制效果呈剂量依赖性。SB 202190本身就足以诱导Jurkat细胞和Hela细胞的死亡：通过激活CPP 32样半胱氨酸蛋白酶，可阻断Bcl - 2的表达。p38β可减轻而p38α可加剧由SB 202190诱导的细胞凋亡^[2]。在HaCaT细胞中SB 202190强烈抑制由紫外线诱导的cox - 2蛋白表达和 mRNA水平^[3]。用SB 202190处理肾小管上皮细胞（正常大鼠k肝脏-52E），可将由白蛋白引发的炎症（单核细胞趋化蛋白-1，MCP - 1）或肿瘤生长因子β-1（TGFβ-1）引发的原纤维化（原骨胶原I a1，procollagen-i alpha1）相关基因降低50%^[4]。SB 202190处理A549细胞，可诱导JNK磷酸化（该磷酸化效应呈时间和剂量依赖性）、转录因子ATF - 2磷酸化，并增加AP – 1与DNA的结合^[6]。SB 202190处理促进THP-1和MV4-11细胞的生长。SB 202190可提高c-Raf 和ERK（细胞外信号调节激酶）磷酸化，暗示由SB 202190诱导的白血病细胞增殖过程有Ras-Raf-MEK-mitogen激活的MAPK通路的参与^[7]。
激酶实验	体外酶活检测
激酶实验	p38α 和 p38β 溶解在25mM的Tris - HCl缓冲液中，PH 7.5，含0.1mM EGTA，髓鞘碱性蛋白（0.33毫克/毫升）作为底物。人工操作条件用50μL [γ-³³P]ATP于30 °C孵育10分钟；Biomek 2000自动化工作站用25μL [γ-³³P]ATP在96孔板室温孵育40分钟。ATP和乙酸镁浓度分别为0.1mM和10mM。所有检测都用MgATP起始。人工检测将孵育液滴到磷酸纤维素纸上，浸泡在50mM磷酸中。用5μL磷酸终止反应，后将孵育液点滴在P30过滤垫上。滤膜在50mM磷酸中漂洗四次以去除ATP，在用丙酮（人工孵育）或甲醇（工作站孵育）处理后，干燥并用放射性计量。
细胞实验	细胞系	Jurkat, 和 HeLa细胞
	浓度	溶解于DMSO, 终浓度~50 μM
	孵育时间	24 小时
	方法	细胞血清饥饿后，用不同浓度SB 202190处理24小时。用台盼蓝或PI染色后经流式细胞仪分析，以检测细胞活力。凋亡细胞核用H33258染色。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2 pJNK1 / pJNK2 / JNK1 / JNK2		26844273
	Immunofluorescence	p-p38 / MMP9		24479681
	Growth inhibition assay	Cell viability		26844273

体内研究(In Vivo)
体内研究活性	SB 202190通过抑制p38减弱了由人脊髓灰质炎IgG（PV-IgG）在被动转移小鼠模型中诱发的水泡形成^[5]。在脓毒症内毒素模型中，与对照组相比，经SB 202190处理可显著提高存活率^[8]。
动物实验	Animal Models	C57BL/6J 小鼠皮内注射无菌的对照IgG或人脊髓灰质炎IgG做对比。
	Dosages	12.5 μg
	Administration	皮内注射

参考文献
[1] Davies SP, et al. Biochem J, 2000, 351(Pt 1), 95-105. [2] Nemoto S, et al. J Biol Chem, 1998, 273(26), 16415-16420. [3] Chen W, et al. Oncogene, 2001, 20(29), 3921-3926. [4] Prakash J, et al. J Pharmacol Exp Ther, 2006, 319(1), 8-19. [5] Berkowitz P, et al. Proc Natl Acad Sci U S A, 2006, 103(34), 12855-12860. [6] Muniyappa H, et al. Cell Signal, 2008, 20(4), 675-683. [7] Hirosawa M, et al. Leuk Res, 2009, 33(5), 693-699. [8] Adrian W OSullivan, et al. J Surg Res . 2009 Mar;152(1):46-53. [9] Paillas S, et al. Cancer Res, 2011, 71(3), 1041-1049. [10] Tsai MS, et al. Mol Cancer Ther, 2012, 11(3), 561-571. [11] Kazuki Hattori, et al. EMBO Rep . 2017 Nov;18(11):2067-2078. + 展开

参考文献

+ 展开

化学信息&溶解度

分子量	331.34	分子式	C₂₀H₁₄N₃OF
CAS号	152121-30-7	SDF	Download SB202190 SDF
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 66 mg/mL ( (199.19 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 22 mg/mL

Water : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):